I think the problem with what you suggest...two primary endpoints, one each for crestor and lipitor, I believe that would have required substnatially more patient years, thus a bigger trial.  Resverlogix, since I have been invested, has always been a cash poor company....forced to operate on the money that Don is able to rasie....maybe if they had a better communications strategy they'd have been more successful in raising the cash they've needed but that's all water under the bridge now.